Drugs / HCL001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07488546 | Sep 2025 → Apr 2027 expected | cirrhosis of liver | Shanghai Huicun Medical Technology Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06306781 | Mar 2024 → Jul 2026 overdue | cirrhosis of liver | RenJi Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCL001 | “HCL001 Cell Injection” NCT07488546 ↗ |
| Modality | Cell therapy | “HCL001 cell (homologous allogeneic hepatocytes) injection” NCT06306781 ↗ |
| Route | Other | “HCL001 cell injection will be slowly infused through the catheter” NCT06306781 ↗ |